Long non-coding RNA MALAT1 regulates hyperglycaemia induced inflammatory process in the endothelial cells

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 6, 2015, Pages 1418-1425

  Puthanveetil, Prasanth ^a   Chen, Shali ^a   Feng, Biao ^a   Gautam, Anirudh ^a   Chakrabarti, Subrata ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

Diabetes; Endothelial cells; Glucose; IL6; Kidney; MALAT1; TNF

Indexed keywords

ANIMALIA;

AUTACOID; GLUCOSE; GLUCOSE BLOOD LEVEL; INTERLEUKIN 6; LONG UNTRANSLATED RNA; MALAT1 LONG NON-CODING RNA, HUMAN; REACTIVE OXYGEN METABOLITE; SAA3P PROTEIN, HUMAN; SERUM AMYLOID A; TUMOR NECROSIS FACTOR;

ANIMAL; BLOOD; CELL CULTURE; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION; GENETICS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; METABOLISM; MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; BLOOD GLUCOSE; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; GENE EXPRESSION; GLUCOSE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPERGLYCEMIA; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MICE; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, LONG NONCODING; SERUM AMYLOID A PROTEIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929946346     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12576     Document Type: Article

References (16)

1. Xu J, Zou MH. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation. 2009; 120: 1266-86.
2. Tabit CE, Chung WB, Hamburg NM, et al. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord. 2010; 11: 61-74.
3. Berg AH, Scherer PH. Adipose tissue, inflammation, and cardiovascular disease. Circulation Res. 2005; 96: 939-49.
4. Zhang B, Arun G, Mao YS, et al. The lncRNA Malat1 is dispensable for mouse development but its transcription plays a cis-regulatory role in the adult. Cell Rep. 2012; 2: 111-23.
5. Tripathi V, Shen Z, Chakraborty A, et al. Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet. 2013; 9: 1-18. Doi:10.1371/journal.pgen.10033682013.
6. Guo F, Li Y, Liu Y, et al. Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion. Acta Biochim Biophys Sin. 2010; 42: 224-9.
7. Gutschner T, Hämmerle M, Diederichs S. MALAT1 - a paradigm for long noncoding RNA function in cancer. J Mol Med. 2013; 91: 791-801.
8. Yan B, Tao ZF, Li XM, et al. Aberrant expression of long noncoding RNAs in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 2014; 55: 941-51.
9. Han CY, Subramanian S, Chan CK, et al. Adipocyte-derived serum amyloid A3 and hyaluronan play a role in monocyte recruitment and adhesion. Diabetes. 2007; 56: 2260-73.
10. Larson MA, Wei SH, Weber A, et al. Induction of human mammary-associated serum amyloid A3 expression by prolactin or lipopolysaccharide. Biochem Biophys Res Commun. 2003; 301: 1030-7.
11. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010; 107: 1058-70.
12. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diab Res. 2007; Doi:10.1155/2007/95103.
13. Wahlestedt C. Targeting long non-coding RNA to therapeutically upregulate gene expression. Nat Rev Drug Discov. 2013; 12: 433-46.
14. Hackermüller J, Reiche K, Otto C, et al. Cell cycle, oncogenic and tumor suppressor pathways regulate numerous long and macro non-protein coding RNAs. Genome Biol. 2014; 15: R48-58.
15. Watts R, Johnsen VL, Shearer J, et al. Myostatin-induced inhibition of the long noncoding RNA Malat1 is associated with decreased myogenesis. Am J Physiol Cell Physiol. 2013; 304: C995-1001.
16. Deguchi A, Tomita T, Omori T, et al. Serum amyloid A3 binds MD-2 to activate p38 and NF-κB pathways in a MyD88-dependent manner. J Immunol. 2013; 191: 1856-64.